• Mild-moderate ulcerative colitis:
    • Adults: PO 500mg QID
      • May start 1g TDS/QID. Max 4g/day
      • For induction or remission maintenance treatment: Start 500mg BD/QID if GI intolerant
    • Children:
      • Initial: PO 40-60mg/kg/day divided every 4-8 hours
      • Maintenance: PO 30 mg/kg/day divided QID
  • Rheumatoid arthritis:
    • PO 1g BD
    • Start 0.5-1g/day divided BD if GI intolerance, then increase dose over 4 weeks
  • Juvenile rheumatoid arthritis:
    • ≥6 years: Gradually titrate at weekly intervals up to PO 30-50mg/kg/day divided BD after meals
      • Max 2g/day
  • Mild-moderate Crohn’s disease (Off-label):
    • PO 3-6 g/day in divided doses for up to 16 weeks

Tablet: 500mg

To be taken after meals

5-Aminosalicylic Acid Derivatives; DMARDs

It is a prodrug that is metabolized to its active components, sulfapyridine and 5-aminosalicylic acid (5-ASA; mesalamine). It blocks cyclooxygenase and inhibits prostaglandin production, producing anti-inflammatory effects

  • Anorexia
  • Headache
  • Nausea
  • Vomiting
  • Dyspepsia
  • Reversible oligospermia
  • Rash
  • Abdominal pain
  • Fever
  • Dizziness
  • Stomatitis
  • Pruritus
  • Abnormal LFTs
  • Leukopenia
  • Urticaria
  • Hemolytic anemia
  • Cyanosis
  • Crystalluria
  • Hematuria
  • Photosensitivity
  • Hypersensitivity to components/class
  • Hypersensitivity to sulfonamides or salicylates
  • Porphyria
  • GI obstruction
  • GU obstruction
  • Influenza (patients <20 years)
  • Varicella (patients <20 years)
  • Febrile viral infection (patients <20 years)
  • BCG live intravesical
  • Lidocaine topical
  • Methenamine
  • Prilocaine topical
  • Talimogene

                          Drug Status

Availability Prescription only
Pregnancy Category B; D if used for prolonged periods or near term
Breastfeeding Not recommended
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Salazopyrine 500mg Tablet 100’s Pfizer Labs Pfizer Labs